MediMix Oncology
  • Home
  • Congresses
    • 2026
      • WCLC 2026
      • ESMO GI 2026
      • ASCO 2026
      • ELCC 2026
      • ENETS 2026
      • BSMO 50 YEARS
      • ASCO GU 2026
      • ASCO GI 2026
    • 2025
      • SABCS 2025
      • SIOG 2025
      • ESMO 2025
      • EADO 2025
  • STiP
  • Webinars
    • ESDO – GI Cancer – ASCO GI 2026
    • ESDO GI Cancer – ESMO 2025
  • Contact
  • Other specialties
    • Dermatology
    • Hematology
    • Respirology
    • Cardiology
    • Rheumatology
    • Neurology
  • SIGN UP
  • SIGN IN
    • Login
    • Account
ELCC 2024Lung Cancer

A propensity-based analysis of SBRT & VATS for early-stage lung cancer

4 April 2024

Dr Olivier Van Kerkhove, pulmonologist in training at UZ Leuven presented a propensity-based analysis of SBRT and VATS for early-stage lung cancer that can guide data-driven support and decision-making in a multidisciplinary tumour board, especially for patients in the ‘grey zone’.

With the educational support of:

You may also be interested in:

ELCC 2024 Daily highlight 2

ELCC 2024 Daily highlight 1

FLAURA2 post-progression outcomes

Tags:

poster

Share Article

Website created by MediMix © 2026 - Privacy Policy

  • Home
  • Congresses
    • 2026
      • WCLC 2026
      • ESMO GI 2026
      • ASCO 2026
      • ELCC 2026
      • ENETS 2026
      • BSMO 50 YEARS
      • ASCO GU 2026
      • ASCO GI 2026
    • 2025
      • SABCS 2025
      • SIOG 2025
      • ESMO 2025
      • EADO 2025
  • STiP
  • Webinars
    • ESDO – GI Cancer – ASCO GI 2026
    • ESDO GI Cancer – ESMO 2025
  • Contact
  • Other specialties
    • Dermatology
    • Hematology
    • Respirology
    • Cardiology
    • Rheumatology
    • Neurology
  • SIGN UP
  • SIGN IN
    • Login
    • Account
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.